Sangamo Therapeutics (SGMO) Stock Price, Quote & News

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 970 6000

Website: www.sangamo.com

Address:

501 Canal Blvd, Richmond, United States

GothamGirl Sep. 12 at 1:45 AM

$SGMO True. In fact, anyone who has been paying attention, including potential partners, knows the CFO is weak. She had no back-up financing plan when PFE dropped Hemo A and she has been dangling Sangamo over a financial cliff ever since. She does not speak on earnings calls! The BOD have probably been working to replace her for months. Potential partners will welcome a capable CFO.

0 · Reply

HershJ Sep. 12 at 1:30 AM

$SGMO who gives a shit about the CFO. That’s just an excuse to manipulate the shares.

0 · Reply

HershJ Sep. 12 at 1:24 AM

$SGMO I hope this keeps going down. I’m buying more shares tomorrow. Thank you, you dumb fcks

0 · Reply

HershJ Sep. 12 at 1:21 AM

$SGMO I’m buying tomorrow. No question. They’re trying to scare the hell out of you. If it dips tomorrow, I’m buying significant amount of shares.

0 · Reply

Newtimmy Sep. 12 at 12:56 AM

$SGMO If the hurricane schedule gets to “ S” this season, you know it, Sandy. My thoughts is that hurricane good SP rockets, or hurricane bad BK or dilute us to .07 cents…

0 · Reply

SilentSniper Sep. 12 at 12:05 AM

$SGMO CFO leaving has no bearing on any partnership discussions…2 BLA ready drugs..great science..great capsid partnerships..matter of time

0 · Reply

Sloppyb Sep. 11 at 11:59 PM

$SGMO Darn..was giving this one more week…. Means most likely no deal in sight…..

0 · Reply

IMAUAP Sep. 11 at 11:51 PM

$SGMO CFO is chasing the AI ghosts.

2 · Reply

Reesifer Sep. 11 at 11:49 PM

$SGMO damn missed this dip

0 · Reply

tapar Sep. 11 at 11:48 PM

$SGMO tomorrow on the announcement of a new ceo will pop up big

0 · Reply

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Aug 8, 2025, 2:53 PM EDT - 4 weeks ago

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 5 weeks ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 31, 2025, 4:05 PM EDT - 6 weeks ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jun 24, 2025, 8:05 AM EDT - 2 months ago

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

May 12, 2025, 9:06 PM EDT - 4 months ago

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025, 6:26 PM EDT - 4 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025, 6:23 PM EDT - 4 months ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025, 4:00 PM EDT - 4 months ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 6, 2025, 4:35 PM EDT - 4 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 8:30 AM EDT - 4 months ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Apr 28, 2025, 4:31 PM EDT - 4 months ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 4, 2025, 2:57 PM EDT - 5 months ago

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Apr 3, 2025, 4:01 PM EDT - 5 months ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Mar 17, 2025, 6:29 PM EDT - 6 months ago

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:01 PM EDT - 6 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 6 months ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Feb 6, 2025, 8:05 AM EST - 7 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Jan 15, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 14, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 8 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 10, 2025, 10:00 AM EST - 8 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 8, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 7, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 6, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 5, 2025, 10:00 AM EST - 8 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Jan 2, 2025, 6:00 PM EST - 9 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Jan 2, 2025, 4:00 PM EST - 9 months ago

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Jan 2, 2025, 3:05 PM EST - 9 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Jan 2, 2025, 10:15 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation

Dec 31, 2024, 12:01 PM EST - 9 months ago

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31, 2024, 11:22 AM EST - 9 months ago

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

PFE

GothamGirl Sep. 12 at 1:45 AM

0 · Reply

HershJ Sep. 12 at 1:30 AM

$SGMO who gives a shit about the CFO. That’s just an excuse to manipulate the shares.

0 · Reply

HershJ Sep. 12 at 1:24 AM

$SGMO I hope this keeps going down. I’m buying more shares tomorrow. Thank you, you dumb fcks

0 · Reply

HershJ Sep. 12 at 1:21 AM

$SGMO I’m buying tomorrow. No question. They’re trying to scare the hell out of you. If it dips tomorrow, I’m buying significant amount of shares.

0 · Reply

Newtimmy Sep. 12 at 12:56 AM

$SGMO If the hurricane schedule gets to “ S” this season, you know it, Sandy. My thoughts is that hurricane good SP rockets, or hurricane bad BK or dilute us to .07 cents…

0 · Reply

SilentSniper Sep. 12 at 12:05 AM

$SGMO CFO leaving has no bearing on any partnership discussions…2 BLA ready drugs..great science..great capsid partnerships..matter of time

0 · Reply

Sloppyb Sep. 11 at 11:59 PM

$SGMO Darn..was giving this one more week…. Means most likely no deal in sight…..

0 · Reply

IMAUAP Sep. 11 at 11:51 PM

$SGMO CFO is chasing the AI ghosts.

2 · Reply

Reesifer Sep. 11 at 11:49 PM

$SGMO damn missed this dip

0 · Reply

tapar Sep. 11 at 11:48 PM

$SGMO tomorrow on the announcement of a new ceo will pop up big

0 · Reply

tapar Sep. 11 at 11:47 PM

$SGMO is resignation is a good news i don't know why people overreact

0 · Reply

Prittykitty Sep. 11 at 11:44 PM

$SGMO it just cannot be this bad 😆 crsp gained 400m in cap today. They should buy sgmo off today's move alone for 1.50 and watch their cap add 2 to 3b off the acquisition. For Sale!!!!!

0 · Reply

Swamp_Yankee Sep. 11 at 11:42 PM

$SGMO If this drops to the .30's I will load "the boat".

0 · Reply

tapar Sep. 11 at 11:42 PM

$SGMO Is resignation for is a good new i dont know why people overreacting

0 · Reply

Crash_Bash Sep. 11 at 11:42 PM

$SGMO she was the most incompetent cfo that we could have. Remebered she is the one that diluted us during earnings call. She is the reason probably not able to negotiate good capsid terms and allowing low ball offer. No offence but i worked a lot with indian people, and they tend to be very weak in negotiations and always get lowballed in offers.

0 · Reply

Crash_Bash Sep. 11 at 11:38 PM

$SGMO She found an AI job at another indian microsoft call center scam lol. Her leaveing is a long time due!

0 · Reply

dmoney9975 Sep. 11 at 11:33 PM

$SGMO sure as shit wasn’t going to be Sandy taking the blame for this funding fiasco. Doesn’t necessarily mean anything short term other than it hasn’t been working out which we all know

0 · Reply

SilentSniper Sep. 11 at 11:09 PM

$SGMO I think there might be more opportunity to buy low 40s ..get ready

0 · Reply

SilentSniper Sep. 11 at 11:04 PM

$SGMO seller exhausted? Can add more low 40s

1 · Reply

SilentSniper Sep. 11 at 10:58 PM

$SGMO Well her salary was $1.18M let Sandy take his sweet time to find a replacement and let her do part time job during this cash crunch…until Fabry partner steps in https://www.salary.com/research/executive-compensation/prathyusha-duraibabu-executive-member-of-sangamo-therapeutics-inc

0 · Reply

JSInvestments Sep. 11 at 10:55 PM

$SGMO wait .. aren’t us bulls on the board begging for C-suite changes?

1 · Reply

TangoToEvora Sep. 11 at 10:54 PM

$SGMO Adding tomorrow. Great opportunity to avg down

0 · Reply

Market Cap	158.40M
Revenue (ttm)	57.80M
Net Income (ttm)	-97.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-169.45%
Debt to Equity Ratio	0.00

Volume	5,118,300
Avg Vol	5,537,444
Day's Range	N/A - N/A
Shares Out	301.71M
Stochastic %K	69%
Beta	1.20
Analysts	Strong Sell
Price Target	$4.10